Physician profile

Cathy Swain-Jones

Obstetrics & Gynecology · Metairie, LA

NPI 1235271834

$219.93

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

See the full distribution for Obstetrics & Gynecology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$143.73
Education$19.27

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Pfizer INC. $62.66 2021-2023
Sumitomo Pharma America, INC. $31.72 2024 Myfembree
Myriad Genetic Laboratories, INC. $27.54 2022
Bayer Healthcare Pharmaceuticals INC. $27.15 2024
Mayne Pharma Commercial LLC $21.01 2024
Gynesonics, INC. $17.22 2024 Sonata Sonography-Guided Transcervical Fibroid Ablation System
Organon LLC $16.43 2024
Abbvie INC. $16.20 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Cathy Swain-Jones

$219.93

in general payments reported 2019-2025

Years
2021-2024
Top company
Pfizer INC.

https://glasscript.com/doctor/512499/cathy-swain-jones

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.